drugset
drugset / Trial / NCT05460195

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

NCT05460195 ↗

Phase 2 Unknown 42 enrolled Shanghai Chest Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

To study the efficacy of sintilimab combined with anlotinib for perioperative non-small cell lung cancer. To explore the clearance effect of sintilimab combined with anlotinib for postoperative adjuvant therapy based on evaluating minimal residual disease.

Timeline

Start
2022-01-01
Primary completion
2024-09-30
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg —
Subject Sintilimab Monoclonal antibody 200 mg —

Indications

non-small cell lung carcinoma